Emistat 4 mg/5 ml

Prevention and treatment of nausea and vomiting caused by cancer chemotherapy and radiotherapy, and prevention and treatment of post-operative nausea and vomiting.

Ondansetron is a selective serotonin 5-HT3 receptor antagonist. It blocks the serotonin receptors in the gut and in the chemoreceptor trigger zone that initiate the vomiting reflex.

Chemotherapy or radiotherapy (adult): 8 mg by mouth 1 to 2 hours before treatment, or 8 mg by slow intravenous or intramuscular injection immediately before treatment, then 8 mg by mouth every 12 hours for up to 5 days. Post-operative nausea and vomiting (adult): 16 mg by mouth 1 hour before anaesthesia, or 4 mg by intramuscular or slow intravenous injection at induction of anaesthesia. Child: dose according to body weight or body surface area, as directed by the physician. Moderate or severe liver impairment: maximum 8 mg daily.

Headache, constipation, a sensation of warmth or flushing and injection-site reactions. Rarely hiccups, dizziness, raised liver enzymes and heart rhythm disturbance (QT prolongation).

Use with caution in patients with QT prolongation, heart rhythm problems or electrolyte disturbance and in intestinal obstruction. Reduce the dose in moderate or severe liver impairment. Use in pregnancy and breast-feeding only if advised by the physician.

Hypersensitivity to ondansetron or other 5-HT3 receptor antagonists. Concomitant use with apomorphine. Congenital long QT syndrome.

Store below 30°C in a cool, dry place, away from light. Keep out of the reach of children.